CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

COVID-19 Update

Last updated: April 6, 2021
Product Line: New at CADTH
Result type: Report

CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.

Our COVID-19 Evidence Portal contains the latest COVID-19 information from CADTH and other respected organizations. Content is updated daily to reflect the rapidly changing and increasing international scientific evidence related to this disease.

The following is a summary of the most recent information posted to our COVID-19 portal.


COVID-19 Impact on Intimate Partner Violence and Child Maltreatment

  • This report (last updated on March 30, 2021) provides an overview of the evidence regarding the impact of COVID-19 and related restrictions on intimate partner violence and child maltreatment.
  • It also includes information on risk factors for violence, access to support for those at risk, and measures to mitigate the risk of intimate partner violence and child maltreatment during this period. The findings of this report are based on a focused literature review.

Ongoing Trials for Drugs in the Prevention and Treatment of COVID-19

  • This report provides information on ongoing randomized controlled trials of drugs being investigated to treat or prevent COVID-19.
  • This report was last updated on March 26, 2021 and gets updated every 2 weeks.
  • Ongoing trials of vaccines and plasma-based therapies are addressed in separate CADTH reports.

COVID-19 News

Visit our COVID-19 news page to stay on top of all the emerging information we are monitoring and updating. Here’s the latest news:

  • Monoclonal Antibody, Leronlimab
    On March 23, Health Canada received an application for leronlimab under its Interim Order for COVID-19 and it is currently under review.
  • Lenzilumab for COVID-19 pneumonia
    A phase III trial of lenzilumab (a GM-CSF monoclonal antibody) has been completed; the results are available in a news release.
  • Interleukin-6 Receptor Antagonists: Tocilizumab and Sarilumab
    In a , CADTH assessed 11 randomized controlled trials, including the preliminary results from the RECOVERY trial preprint.

CADTH Literature Searching Tools

To help conduct your COVID-19–related literature searches, see our COVID-19 Search Strings and our COVID-19 Grey Literature Resources.

Additional Resources

CADTH is pleased to showcase additional COVID-19 resources from our partner organizations and the Canadian federal, provincial, and territorial governments’ health jurisdictions:


Canadian ministries and departments of health, publicly funded organizations responsible for health service delivery, and clinical society stakeholders are encouraged to submit a request or contact their CADTH Liaison Officer. We’re here to help.

The CADTH Weekly COVID-19 Update is intended to keep you informed about the latest information posted on the CADTH COVID-19 portal.